|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011860,
umls-concept:C0016017,
umls-concept:C0020443,
umls-concept:C0030190,
umls-concept:C0030705,
umls-concept:C0255161,
umls-concept:C0332281,
umls-concept:C0332307,
umls-concept:C0684336,
umls-concept:C0948265,
umls-concept:C1280500,
umls-concept:C1413666,
umls-concept:C1442792
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2005-8-26
|
|
pubmed:abstractText |
To determine whether plasma concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI) in patients with type 2 diabetes were associated with components of metabolic syndrome (MS), including high-sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor (PAI)-1, and LDL cholesterol.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0149-5992
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2211-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16123492-Adult,
pubmed-meshheading:16123492-Aged,
pubmed-meshheading:16123492-Alanine Transaminase,
pubmed-meshheading:16123492-Body Mass Index,
pubmed-meshheading:16123492-C-Reactive Protein,
pubmed-meshheading:16123492-Carboxypeptidase U,
pubmed-meshheading:16123492-Cholesterol, LDL,
pubmed-meshheading:16123492-Diabetes Mellitus, Type 2,
pubmed-meshheading:16123492-Female,
pubmed-meshheading:16123492-Humans,
pubmed-meshheading:16123492-Hypercholesterolemia,
pubmed-meshheading:16123492-Inflammation,
pubmed-meshheading:16123492-Insulin,
pubmed-meshheading:16123492-Insulin Resistance,
pubmed-meshheading:16123492-Male,
pubmed-meshheading:16123492-Metabolic Syndrome X,
pubmed-meshheading:16123492-Middle Aged,
pubmed-meshheading:16123492-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:16123492-Thrombolytic Therapy,
pubmed-meshheading:16123492-Triglycerides
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
|
|
pubmed:affiliation |
Department of Internal Medicine, Koshigaya Hospital, Dokkyo University School of Medicine, 2-1-50 Minami-Koshigaya, Koshiagya, Saitama 343-8555, Japan. yaso@dokkyomed.ac.jp
|
|
pubmed:publicationType |
Journal Article
|
